Overview of serotonin syndrome

Annals of Clinical Psychiatry

Volumn 24, Issue 4, 2012, Pages 310-318

  Iqbal, Mohammad M ^a,b   Basil, Miles J ^c   Kaplan, Jonathan ^a   Iqbal, Touhid ^d,e  

^a MANHATTAN PSYCHIATRIC CENTER   (United States)

^b State University of New York Upstate Medical University: College of Medicine   (United States)

^c UNIVERSITY AT BUFFALO   (United States)

^d SUNY UPSTATE MEDICAL UNIVERSITY   (United States)

^e SYRACUSE UNIVERSITY   (United States)

Author keywords

5 hydroxytryptamine; Antidepressants; Neuroleptic malignant syndrome; Selective serotonin reuptake inhibitors; Serotonergic agents; Serotonin syndrome

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; AMINE OXIDASE (FLAVIN CONTAINING); AMPHETAMINE; ANTIMIGRAINE AGENT; BUSPIRONE; CHLORPROMAZINE; COCAINE; CYPROHEPTADINE; DEXTROMETHORPHAN; DIETHYLAMINE; FENTANYL; HYPERICUM PERFORATUM EXTRACT; LINEZOLID; LYSERGIC ACID; METHADONE; METHYLPHENIDATE; MONOAMINE OXIDASE INHIBITOR; PETHIDINE; PHENELZINE; RESERPINE; SEROTONIN; SEROTONIN AGONIST; SEROTONIN ANTAGONIST; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN RECEPTOR; SEROTONIN UPTAKE INHIBITOR; TRAMADOL; TRICYCLIC ANTIDEPRESSANT AGENT; TRYPTOPHAN; UNINDEXED DRUG;

ATAXIA; AUTONOMIC DYSFUNCTION; AUTONOMIC DYSREFLEXIA; CLINICAL PRACTICE; DEPRESSION; DIAGNOSTIC ERROR; DIAPHORESIS; DIFFERENTIAL DIAGNOSIS; DISEASE SEVERITY; DRUG MEGADOSE; DRUG WITHDRAWAL; EPIDEMIOLOGICAL DATA; FLUID THERAPY; HOSPITALIZATION; HUMAN; MALIGNANT HYPERTHERMIA; MEDLINE; MENTAL INSTABILITY; MUSCLE TONE; NEUROMUSCULAR DISEASE; PRIORITY JOURNAL; PROGNOSIS; RESTLESSNESS; REVIEW; SEDATION; SEROTONIN SYNDROME; SIDE EFFECT;

DRUG COMBINATIONS; DRUG INTERACTIONS; HUMANS; MONOAMINE OXIDASE INHIBITORS; SEROTONIN AGENTS; SEROTONIN SYNDROME;

EID: 84872339130     PISSN: 10401237     EISSN: 15473325     Source Type: Journal    
DOI: None     Document Type: Review

References (83)

1. Sternbach H. The serotonin syndrome. Am J Psychiatry. 1991;148:705-713.
2. Buck ML. Serotonin syndrome: pediatric and neonatal considerations. Pediatric Pharmacotherapy. 2006:12:1-5.
3. Boyer EW, Shannon M. The serotonin syndrome. N Engl J Med. 2005;352:1112-1120.
4. Jones D, Story DA. Serotonin syndrome and the anaesthetist. Anaesth Intensive Care. 2005;33:181-187. (Pubitemid 40521017)
5. Huang V, Gortney JS. Risk of serotonin syndrome with concomitant administration of linezolid and serotonin agonists. Pharmacotherapy. 2006;26:1784-1793. (Pubitemid 44885332)
6. Keegan MT, Brown DR, Rabinstein AA. Serotonin syndrome from the interaction of cyclobenzaprine with other serotoninergic drugs. Anesth Analg. 2006;103:1466-1468. (Pubitemid 44949216)
7. D'Esposito M. Serotonin neurotoxicity: implications for cognitive neuroscience and neurology. Neurology. 1998;51:1529-1530. (Pubitemid 28565226)
8. Parker V, Wong AH, Boon HS, et al. Adverse reactions to St John's Wort. Can J Psychiatry. 2001;46:77-79. (Pubitemid 32209349)
9. Strouse TB, Kerrihard TN, Forscher CA, et al. Serotonin syndrome precipitated by linezolid in a medically ill patient on duloxetine. J Clin Psychopharmacol. 2006;26:681-683. (Pubitemid 44772758)
10. Isbister GK, Hackett LP, Dawson AH, et al. Moclobemide poisoning: toxicokinetics and occurrence of serotonin toxicity. Br J Clin Pharmacol. 2003;56:441-450. (Pubitemid 37188140)
11. Sovner R, Wolfe J. Interaction between dextromethorphan and monoamine oxidase inhibitor therapy with isocarboxazid. N Engl J Med. 1988;319:1671. (Pubitemid 19015244)
12. Bhatara VS, Bandettini FC. Possible interaction between sertraline and tranylcypromine. Clin Pharm. 1993;12:222-225. (Pubitemid 23062863)
13. Marley E, Wozniak KM. Interactions of non-selective monoamine oxidase inhibitors, tranylcypromine and nialamide, with inhibitors of 5-hydroxytryptamine, dopamine or noradrenaline re-uptake. J Psychiatr Res. 1984;18:191-203. (Pubitemid 14081923)
14. Hall M, Buckley N. Serotonin syndrome. Australian Prescriber. 2003;26:62-63. (Pubitemid 36644404)
15. Keck PE Jr, Arnold LM. Serotonin syndrome. Psychiatr Ann. 2000;30:333-343.
16. Wooltorton E. Triptan migraine treatments and antidepressants: risk of serotonin syndrome. CMAJ. 2006;175:874.
17. Westphal RJ. Serotonin syndrome. J Am Psychiatr Nurses Assoc. 1999;5:97-102.
18. Gill M, LoVecchio F, Selden B. Serotonin syndrome in a child after a single dose of fluvoxamine. Ann Emerg Med. 1999;33:457-459. (Pubitemid 29157574)
19. Demirkiran M, Jankovic J, Dean JM. Ecstasy intoxication: an overlap between serotonin syndrome and neuroleptic malignant syndrome. Clin Neuropharmacol. 1996;19:157-164. (Pubitemid 26099372)
20. Milnacipran (savella) for fibromyalgia. Med Lett Drugs Ther. 2009;51:45-46.
21. Rajapakse S, Abeynaike L, Wickramarathne T. Venlafaxine-associated serotonin syndrome causing severe rhabdomyolysis and acute renal failure in a patient with idiopathic Parkinson disease. J Clin Psychopharmacol. 2010;30:620-622.
22. Thomas JM, Rubin EH. Case report of a toxic reaction from a combination of tryptophan and phenelzine. Am J Psychiatry. 1984;141:281-283. (Pubitemid 14180978)
23. Guzé BH, Baxter LR Jr. The serotonin syndrome: case responsive to propranolol. J Clin Psychopharmacol. 1986;6:119-120.
24. Smilkstein MJ, Smolinske SC, Rumack BH. A case of MAO inhibitor/MDMA interaction: agony after ecstasy. J Toxicol Clin Toxicol. 1987;25:149-159. (Pubitemid 17117468)
25. Pearson HJ. Interaction of fluoxetine with carbamazepine. J Clin Psychiatry. 1990;51:126. (Pubitemid 20107913)
26. Iruela LM, Minguez L, Merino J, et al. Toxic interaction of S-adenosylmethionine and clomipramine. Am J Psychiatry. 1993;150:522.
27. Goldberg RJ, Huk M. Serotonin syndrome from trazodone and buspirone. Psychosomatics. 1992;33:235-236.
28. Neuvonen PJ, Pohjola-Sintonen S, Tacke U, et al. Five fatal cases of serotonin syndrome after moclobemide-citalopram or moclobemide-clomipramine overdoses. Lancet. 1993;342:1419. (Pubitemid 23361248)
29. Insel TR, Roy BF, Cohen RM, et al. Possible development of the serotonin syndrome in man. Am J Psychiatry. 1982;139:954-955. (Pubitemid 12096541)
30. Ooi TK. The serotonin syndrome. Anaesthesia. 1991;46:507-508.
31. Brannan SK, Talley BJ, Bowden CL. Sertraline and isocarboxazid cause a serotonin syndrome. J Clin Psychopharmacol. 1994;14:144-145. (Pubitemid 24120714)
32. Sandyk R. L-dopa induced "serotonin syndrome" in a parkinsonian patient on bromocriptine. J Clin Psychopharmacol. 1986;6:194-195.
33. Mitchell RS. Fatal toxic encephalitis occurring during iproniazid therapy in pulmonary tuberculosis. Ann Intern Med. 1955;42:417-424.
34. Gillman PK. Serotonin syndrome: history and risk. Fundam Clin Pharmacol. 1998;12:482-491. (Pubitemid 29166491)
35. Arora B, Kannikeswaran N. The serotonin syndrome - the need for physician's awareness. Int J Emerg Med. 2010;3:373-377.
36. Sorenson S. Serotonin syndrome. Utox Update. 2002;4:1-2.
37. Oates JA, Sjoerdsma A. Neurologic effects of tryptophan in patients receiving a monoamine oxidase inhibitor. Neurology. 1960;10:1076-1078.
38. Mackay FJ, Dunn NR, Mann RD. Antidepressants and the serotonin syndrome in general practice. Br J Gen Pract. 1999;49:871-874. (Pubitemid 29504898)
39. Isbister GK, Bowe SJ, Dawson A, et al. Relative toxicity of selective serotonin reuptake inhibitors (SSRIs) in overdose. J Toxicol Clin Toxicol. 2004;42:277-285. (Pubitemid 39166756)
40. Asch DA, Parker RM. The Libby Zion case. One step forward or two steps backward? N Engl J Med. 1988;318:771-775. (Pubitemid 18090261)
41. Graham PM. Successful treatment of the toxic serotonin syndrome with chlorpromazine. Med J Aust. 1997;166:166-167. (Pubitemid 27085124)
42. Hall RCW, Hall RCW, Chapman MJ. Central serotonin syndrome: Part II - Pathophysiology, drug interactions, and treatment. Clin Geriatr. 2008;16:24-28.
43. Mills KC. Serotonin syndrome. Am Fam Physician. 1995;52:1475-1482.
44. Birmes P, Coppin D, Schmitt L, et al. Serotonin syndrome: a brief review. CMAJ. 2003;168:1439-1442. (Pubitemid 36714045)
45. Mills KC. Serotonin syndrome. A clinical update. Crit Care Clin. 1997;13:763-783.
46. Glennon RA, Dukat M, Westkaemper RB. Serotonin receptor subtypes and ligands. In: Bloom FE, Kupfer DJ, eds. Psychopharmacology: the fourth generation of progress. New York, NY: Raven Press, Ltd; 1995.
47. Bishop JR, Bishop DL. How to prevent serotonin syndrome from drug-drug interactions. Current Psychiatry. 2011;10:81-83.
48. Nelson LS, Erdman AR, Booze LL, et al. Selective serotonin reuptake inhibitor poisoning: an evidence-based consensus guideline for out-of-hospital management. Clin Toxicol (Phila). 2007;45:315-332. (Pubitemid 46718124)
49. Glennon RA. Serotonin receptors: clinical implications. Neurosci Biobehav Rev. 1990;14:35-47. (Pubitemid 20115611)
50. Nisijima K, Yoshino T, Yui K, et al. Potent serotonin (5-HT)(2A) receptor antagonists completely prevent the development of hyperthermia in an animal model of the 5-HT syndrome. Brain Res. 2001;890:23-31. (Pubitemid 32119524)
51. Bodner RA, Lynch T, Lewis L, et al. Serotonin syndrome. Neurology. 1995;45:219-223.
52. Walsh J. Serotonin syndrome. Anaesthesia Tutorial of the Week. 2010;1-5.
53. Dvir Y, Smallwood P. Serotonin syndrome: A complex but easily avoidable condition. Gen Hosp Psychiatry. 2008;30:284-287. (Pubitemid 351538958)
54. Thanacoody RHK. Serotonin syndrome. Adverse Drug React Bull. 2007;243:931-934. (Pubitemid 47607235)
55. Gelener P, Gorgulu U, Kutlu G, et al. Serotonin syndrome due to duloxetine. Clin Neuropharmacol. 2011;34:127-128.
56. Isbister GK, Buckley NA. The pathophysiology of serotonin toxicity in animals and humans: implications for diagnosis and treatment. Clin Neuropharmacol. 2005;28:205-214. (Pubitemid 41579617)
57. Radomski JW, Dursun SM, Reveley MA, et al. An exploratory approach to the serotonin syndrome: an update of clinical phenomenology and revised diagnostic criteria. Med Hypotheses. 2000;55:218-224.
58. Martin TG. Serotonin syndrome. Ann Emerg Med. 1996;28:520-526. (Pubitemid 26367413)
59. Kaneda Y, Ishimoto Y, Ohmori T. Mild serotonin syndrome on fluvoxamine. Int J Neurosci. 2001;109:165-172. (Pubitemid 32832163)
60. Lantz MS. Serotonin syndrome. A common but often unrecognized psychiatric condition. Geriatrics. 2001;56:52-53. (Pubitemid 32053201)
61. Garside S, Rosebush PI. Serotonin syndrome: not a benign toxidrome. CMAJ. 2003;169:543. (Pubitemid 37174592)
62. Adnet P, Lestavel P, Krivosic-Horber R. Neuroleptic malignant syndrome. Br J Anaesth. 2000;85:129-135. (Pubitemid 30417228)
63. Hegerl U, Bottlender R, Gallinat J, et al. The serotonin syndrome scale: first results on validity. Eur Arch Psychiatry Clin Neurosci. 1998;248:96-103. (Pubitemid 28279551)
64. Isbister GK, Buckley NA, Whyte IM. Serotonin toxicity: a practical approach to diagnosis and treatment. Med J Aust. 2007;187:361-365.
65. Jacobs BL. An animal behavior model for studying central serotonergic synapses. Life Sci. 1976;19:777-785.
66. Dunkley EJ, Isbister GK, Sibbritt D, et al. The Hunter Serotonin Toxicity Criteria: simple and accurate diagnostic decision rules for serotonin toxicity. QJM. 2003;96:635-642. (Pubitemid 37063272)
67. Ables AZ, Nagubilli R. Prevention, recognition, and management of serotonin syndrome. Am Fam Physician. 2010;81:1139-1142.
68. Wappler F. Malignant hyperthermia. Eur J Anaesthesiol. 2001;18:632-652. (Pubitemid 32939480)
69. Frommer DA, Kulig KW, Marx JA, et al. Tricyclic anti-depressant overdose. A review. JAMA. 1987;257:521-526.
70. Hasan S, Buckley P. Novel antipsychotics and the neuroleptic malignant syndrome: a review and critique. Am J Psychiatry. 1998;155:1113-1116. (Pubitemid 28357742)
71. Rosenberg H, Davis M, James D, et al. Malignant hyperthermia. Orphanet J Rare Dis. 2007;2:21.
72. Gronert GA, Pessah IN, Muldoon SM, et al. Malignant hyperthermia. In: Miller RD, ed. Miller's anesthesia. 6th ed. Philadelphia, PA: Elsevier Churchill Livingston; 2005:1169-1190.
73. Odagaki Y. Atypical neuroleptic malignant syndrome or serotonin toxicity associated with atypical antipsychotics? Curr Drug Saf. 2009;4:84-93.
74. Bhanushali MJ, Tuite PJ. The evaluation and management of patients with neuroleptic malignant syndrome. Neurol Clin. 2004;22:389-411. (Pubitemid 38388555)
75. Keltner NL, Folks DG. Psychotropic drugs. 4th ed. St. Louis, MO: Elsevier; 2005.
76. Sporer KA. The serotonin syndrome. Implicated drugs, pathophysiology and management. Drug Saf. 1995;13:94-104.
77. Gillman PK. The serotonin syndrome and its treatment. J Psychopharmacol. 1999;13:100-109. (Pubitemid 29141280)
78. Mir S, Taylor D. Serotonin syndrome. Psychiatric Bulletin. 1999;23:742-747.
79. Bagley WH, Yang H, Shah KH. Rhabdomyolysis. Intern Emerg Med. 2007;2:210-218.
80. Criddle LM. Rhabdomyolysis. Pathophysiology, recognition, and management. Crit Care Nurse. 2003;23:14- 22, 24-26, 28.
81. Lappin RI, Auchincloss EL. Treatment of the serotonin syndrome with cyproheptadine. N Engl J Med. 1994;331:1021-1022.
82. Chan BS, Graudins A, Whyte IM, et al. Serotonin syndrome resulting from drug interactions. Med J Aust. 1998;169:523-525. (Pubitemid 28519989)
83. Gillman PK. Successful treatment of serotonin syndrome with chlorpromazine. Med J Aust. 1996;165:345-346. (Pubitemid 26328905)